To confirm that PROSTVAC immunotherapy induced a productive and functional tumor-infiltrating T cell response, CD8 and CD4 TILs were analyzed for effector and memory T cell markers (KLRG-1 and CD127) and the CD62L‒ CD44hi activation phenotype. This evidence concerns the gene KLRG1 and neoplasm.